Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

MoneyGroupLLC Dec. 7 at 5:05 AM

Enter: $AVXL Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $0.73 - $0.80 Sell Price: $1.10 Profit : +51% (Turn every $1 into $1.51) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Georgejj Dec. 7 at 4:45 AM

$AVXL Is Donald J. Trump on a mab for the treatment of Alzheimer's disease??? https://www.express.co.uk/news/world/2142937/donald-trump-health-fears-congresswoman Should Donald J. Trump be taking daily blarcamesine pills for the treatment of Alzheimer's disease instead. Good luck and GOD bless,

0 · Reply

AntonioChigurh Dec. 7 at 3:38 AM

$AVXL POS Shitkreli had a heads up from EMA discussion prior to Anavex PR of downtrend. If coming March he loads up again publicly shorting Anavex beware for rejection.

1 · Reply

SCLXSUX Dec. 7 at 1:04 AM

$AVXL - Yes. There's a definite probability we could receive conditional or full approval! Of course, there's the possibility that we may not...But we will find out soon enough. WE SHALL SEE!!!

1 · Reply

Sand_Pebble Dec. 7 at 12:54 AM

$AVXL I sometimes buy a lottery ticket if the jackpot is super large or if it is convenient & if I remember. I almost fully expect to lose but it's a nice day dream, a little piece of hope & the conversation about winning is worth the $2 price tag for me. It's cheap fun. I fully expect Blarcamesine to get a negative CHMP opinion next week but the day dream of some how pulling it off with a narrow positive opinion victory sure is fun to thing about. It doesn't even cost the 2 bucks to think & hope on that?

1 · Reply

Jsgribbs Dec. 7 at 12:48 AM

$AVXL is there a chance at conditional approval next week?

3 · Reply

Barnstormer Dec. 6 at 11:04 PM

$AVXL I am enjoying a nice sunny Saturday afternoon in Southern California, reading through some intelligent posts. Then there is this fight going on between two respectable posters that sounds like a cat fight. Take it outside boys, take a deep breath and come back in and enjoy a glass on me.

1 · Reply

bufnyfan1 Dec. 6 at 9:29 PM

$AVXL The CHMP has ~30 voters/reviewers--the "negative trend" doesn't specify how many of this number were voting--it could be the minority--and they didn't give it a "total negative" and rejected it outright so that means that all the data hasn't been fully analyzed and more data may have been submitted to support blacamesine in the interim-I still hope this vote may still be "up in the air"

3 · Reply

Kb1123 Dec. 6 at 8:05 PM

$AVXL I am still very much of the opinion that Missling MUST partner in order to get this drug across the finish line. BP was able to use their influence to get two dangerous and ineffective treatment across the finish line. It’s imperative to partner with a BP so they can use their influence to push this safe and effective drug across the finish line.

2 · Reply

TwistedNipple Dec. 6 at 6:32 PM

$AVXL Is it me...or is it 'bad' that 273 is so effective, better when administered earlier, and treats a large % of the population? Meaning it will be an immediate cost, for many who are yet to be costing government healthcare systems money. But long term...the systems will in fact save. How does CHMP / EMA weigh in on such things...

1 · Reply

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

Nov 26, 2025, 7:30 AM EST - 11 days ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 25, 2025, 11:53 AM EST - 11 days ago

Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript

Nov 25, 2025, 7:30 AM EST - 12 days ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 19, 2025, 7:30 AM EST - 18 days ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 18, 2025, 7:30 AM EST - 19 days ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 14, 2025, 7:30 AM EST - 23 days ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 1:40 PM EDT - 2 months ago

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Oct 2, 2025, 7:35 AM EDT - 2 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 10:38 AM EDT - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 15, 2025, 8:49 PM EDT - 7 months ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 7 months ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 7 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 10 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 10 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 10 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 10 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 11 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 11 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 11 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 1 year ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 1 year ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 1 year ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

MoneyGroupLLC Dec. 7 at 5:05 AM

0 · Reply

Georgejj Dec. 7 at 4:45 AM

0 · Reply

AntonioChigurh Dec. 7 at 3:38 AM

$AVXL POS Shitkreli had a heads up from EMA discussion prior to Anavex PR of downtrend. If coming March he loads up again publicly shorting Anavex beware for rejection.

1 · Reply

SCLXSUX Dec. 7 at 1:04 AM

$AVXL - Yes. There's a definite probability we could receive conditional or full approval! Of course, there's the possibility that we may not...But we will find out soon enough. WE SHALL SEE!!!

1 · Reply

Sand_Pebble Dec. 7 at 12:54 AM

1 · Reply

Jsgribbs Dec. 7 at 12:48 AM

$AVXL is there a chance at conditional approval next week?

3 · Reply

Barnstormer Dec. 6 at 11:04 PM

1 · Reply

bufnyfan1 Dec. 6 at 9:29 PM

3 · Reply

Kb1123 Dec. 6 at 8:05 PM

2 · Reply

TwistedNipple Dec. 6 at 6:32 PM

1 · Reply

Smellmahass Dec. 6 at 6:19 PM

$AVXL When do we officially find out when ema publishes its decision plsM what day next week?

1 · Reply

Trainguy1 Dec. 6 at 5:34 PM

$AVXL Google says…

3 · Reply

Blarcamesine Dec. 6 at 5:06 PM

$AVXL investors signing a petition saying they want their stock to go . . . Come on now. . Oh boy. You know how far that will go! Let's actually see what the EMA says.

0 · Reply

Blarcamesine Dec. 6 at 4:41 PM

$AVXL Fatal error? Or not? Fatal... 48 week trial. Or the EMA wants a full phase 3 first. If that's the reasons .. it's a no.. ADL MISS .. could go either way Then we have ABCLEAR that passes ADL easily, but then the EMA may claim ad hoc data and say NO or could they try a conditional approval. Lot's of ifs and the whole thing is leaning negatively .. and the FDA? When??

0 · Reply

Sand_Pebble Dec. 6 at 1:52 PM

$AVXL the good news is, I don’t expect share price to fall any today or tomorrow.

0 · Reply

Blarcamesine Dec. 6 at 11:59 AM

$AVXL finally!! This week let's see what the ema says.

2 · Reply

Laei Dec. 6 at 5:49 AM

$AVXL Many thanks to Jesse/Mayo for submitting a professional and well-written letter to the CHMP/EMA. I fear that what they have received from other amateur investors here on the forum is so poor that it does more harm than good.

2 · Reply

PailseyBelle Dec. 6 at 5:25 AM

$AVXL @ItsThrillhouse, the price of $4.44 is a sign of good things to come!

1 · Reply

papatrick Dec. 6 at 5:02 AM

$AVXL Vamvakides still publish. Last summission in 2025. He is approx 85 years old. "The pathomimetic oAβ25–35 model of Alzheimer's disease: potential for screening of new therapeutic" .

0 · Reply

papatrick Dec. 6 at 4:51 AM

$AVXL AI says: After 2015, Dr. Vamvakides is no longer listed as part of the management team or on the board of directors, suggesting his departure occurred sometime between 2009 and July 2013, likely around the time of the leadership change (Missling arrival, didnt like the 6% Royalty) and a reported legal dispute where he sued the company to reclaim his patents.

0 · Reply

papatrick Dec. 6 at 4:25 AM

$AVXL

0 · Reply

papatrick Dec. 6 at 4:20 AM

$AVXL was it expensive to buy the pipeline from Vamvakides? see below:

0 · Reply

Market Cap	393.13M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,077,600
Avg Vol	2,607,294
Day's Range	N/A - N/A
Shares Out	89.35M
Stochastic %K	76%
Beta	1.15
Analysts	Sell
Price Target	$22.00